Carisma Therapeutics (NASDAQ:CARM) Given “In-Line” Rating at Evercore ISI

Evercore ISI reissued their in-line rating on shares of Carisma Therapeutics (NASDAQ:CARM) in a research report released on Wednesday,Benzinga reports. They currently have a $0.70 price target on the stock, down from their previous price target of $4.00.

A number of other equities research analysts also recently issued reports on the stock. HC Wainwright reduced their price target on shares of Carisma Therapeutics from $8.00 to $5.00 and set a “buy” rating for the company in a research report on Monday, November 25th. EF Hutton Acquisition Co. I raised Carisma Therapeutics to a “strong-buy” rating in a report on Wednesday, October 30th. BTIG Research lowered Carisma Therapeutics from a “buy” rating to a “neutral” rating in a report on Tuesday. Finally, D. Boral Capital cut their price target on Carisma Therapeutics from $24.00 to $12.00 and set a “buy” rating for the company in a research note on Monday. Three investment analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $4.94.

Carisma Therapeutics Trading Down 19.7 %

NASDAQ:CARM opened at $0.56 on Wednesday. Carisma Therapeutics has a 1 year low of $0.56 and a 1 year high of $3.16. The company has a debt-to-equity ratio of 1.39, a quick ratio of 3.23 and a current ratio of 3.23. The stock has a fifty day moving average price of $0.92 and a two-hundred day moving average price of $1.05. The stock has a market capitalization of $23.23 million, a price-to-earnings ratio of -0.36 and a beta of 1.44.

Carisma Therapeutics (NASDAQ:CARM) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.31) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.31). Carisma Therapeutics had a negative net margin of 314.78% and a negative return on equity of 957.20%. The business had revenue of $3.39 million during the quarter. As a group, sell-side analysts anticipate that Carisma Therapeutics will post -1.32 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Carisma Therapeutics

Several hedge funds have recently bought and sold shares of CARM. Vanguard Group Inc. lifted its position in shares of Carisma Therapeutics by 0.7% in the first quarter. Vanguard Group Inc. now owns 1,579,961 shares of the company’s stock valued at $3,587,000 after acquiring an additional 11,200 shares in the last quarter. Wexford Capital LP increased its position in Carisma Therapeutics by 75.5% during the 3rd quarter. Wexford Capital LP now owns 34,861 shares of the company’s stock worth $34,000 after purchasing an additional 15,000 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in Carisma Therapeutics in the 2nd quarter valued at about $40,000. Finally, Barclays PLC lifted its holdings in Carisma Therapeutics by 3,661,933.3% in the 3rd quarter. Barclays PLC now owns 549,305 shares of the company’s stock valued at $539,000 after purchasing an additional 549,290 shares in the last quarter. Hedge funds and other institutional investors own 44.27% of the company’s stock.

Carisma Therapeutics Company Profile

Carisma Therapeutics, Inc, a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others.